Market Newsdesk

Johnston, RI, Dec. 15, 2020 (GLOBE NEWSWIRE) — Mobile Beacon is celebrating 10 years of providing high-speed, low-cost, mobile internet access to the anchors of communities: nonprofits, schools, libraries, and healthcare organizations. In honor of this anniversary, we are providing 10 local and national organizations with a $10,000 grant, as well as 10 laptops and 10 hotspots with Mobile Beacon’s, unlimited internet service, in support of their own missions. We are honored to highlight the first four recipients of the Community Grants and the incredible work they are doing in their communities.

Providence Public Library (PPL) – PPL was a perfect candidate for Mobile Beacon’s community grant, due to their diverse community programs such as public education, workforce development, and arts and cultural programming. The 10 laptops and 10 LTE mobile hotspots will be used for PPL’s Data Navigators program, as part of its STEAM-based initiative for teens. PPL inspires Rhode Islanders to be lifelong learners by engaging their curiosity and offering access to extraordinary experiences, resources and ideas. 

Leukemia and Lymphoma Society (LLS) –  Mobile Beacon has been a proud supporter of the LLS organization throughout our history, and our own Sales Manager, Rick Lindholm, served as the LLS board president and is a true advocate of the incredible work LLS does. Mobile Beacon was honored to provide a $10,000 monetary donation to Rick’s Man of the Year campaign, as The Man and Woman of the Year campaigns are philanthropic competitions to support blood cancer research. LLS will utilize the technology donated for families currently undergoing treatment, so students can stay engaged in school work, families can stay connected to their support system, and there is no financial technology burden. 

Federal Hill House – A partner in the Office of Healthy Aging‘s (OHA) digiAGE Collaborative, Federal Hill House is helping to bridge the digital divide for older Rhode Islanders by linking them to the technology and virtual opportunities that underpin modern life. Through Beacon’s support, Federal Hill House will provide smart devices, internet service, and digital literacy training to older adults in communities hit hard by COVID-19 to help them access online resources and virtually connect with family and friends.  

Children’s Friend: Mobile Beacon was proud to support Children’s Friend in their position as the leader in improving the well-being and healthy development of Rhode Island’s most vulnerable young children and families. Children’s Friend will utilize the donated technology to keep their staff connected to support these young children and their families socially, and through distance learning.The $10,000 donation will support their “Spirit of the Holiday Drive,” which provides and distributes essential warm clothing and toys to vulnerable Rhode Island families during the Holiday Season.

Throughout the past 10 years, more than 12,000 nonprofits, schools, and libraries used Mobile Beacon’s unlimited mobile broadband service to serve their communities. Today, organizations in all 50 states currently rely on our broadband service. 

Stay tuned as Mobile Beacon will be announcing additional community grant recipients in 2021.

###

About Mobile Beacon: Founded in 2010, Mobile Beacon provides high-speed, low-cost, mobile internet access to the anchors of communities: nonprofits, schools, libraries, and healthcare organizations. In honor of our 10th anniversary, Mobile Beacon is awarding 10 community grants to anchors of our local community, who embody a similar mission in creating opportunities for underserved groups and investing in our nation’s future. Through the broadband service, Mobile Beacon provides, organizations have an essential tool to fulfill their missions and maximize their philanthropic impact, which allows organizations to access more information, reach more people, and help more in their communities. Learn more at http://www.mobilebeacon.org.

YORK, England, Dec. 15, 2020 (GLOBE NEWSWIRE) — When seasoned sales executive at NTI plc, Victor Stanley, embarks on a business trip to Japan, his goal is to present his electrochemical company’s newest product to Kenezo Nonaka of Nonaka Industries and secure a substantial investment. Instead, he unknowingly enters a dangerous arena filled with shady dealings, criminal masterminds, crooked scientists and a deep thirst for power and money.

In Paul Stephen Hudson’s debut novel, “Bad Chemistry,” readers are taken on an international adventure as multiple people vie for control over NTI’s revolutionary new anti-counterfeiting coating to further their own agendas. While Stanley attempts to safeguard his company’s technology, one of the scientists behind its creation, George Yoreen, is masking an unsavory history with corrupt Korean businessman Lee Doo-hwan. After Doo-hwan learns that Yoreen took part in developing the coating, which threatens to undercut his illegal activities, he blackmails him into handing a sample over.

Doo-hwan enlists his employee, Veronica Tan, to distract Stanley with her feminine charm and help him in his mission to secure the coating. Tan accompanies him to the United Kingdom but is all the while harboring a desire for revenge, as Doo-hwan had wronged her father in the past and contributed to his untimely death. As Stanley, Yoreen, Doo-hwan, Nonaka and Tan compete in a rat race for the anti-counterfeiting technology and control of the market share, their ulterior motives continually undercut their commitments to one another and create an exciting, fast-paced story with twists and turns throughout.

“It’s an exceptionally well-written chronicle of international intrigue and suspense,” wrote Joe Kilgore for The US Review of Books. “A contemporary thriller that spans the globe, there is literary heft to this novel as well. It is like a John le Carre spellbinder without the spies and counterspies.”

“Action-packed, tension-filled and a lengthy yet entertaining read, author Paul Stephen Hudson’s “Bad Chemistry” is a wonderful thriller that keeps readers interested and excited throughout the entirety of the novel,” wrote Tony Espinoza for Pacific Book Review. 

“Bad Chemistry”
By Paul Stephen Hudson
ISBN: 9781664124158 (softcover); 9781664124141 (hardcover); 9781664125834 (electronic)
Available from Amazon, Barnes & Noble and Xlibris

About the author
Paul Stephen Hudson is an author and semi-retired international businessman. He enjoyed a traditional British Public School education followed by a short career in the British Armed Forces before going into the chemical industry. Throughout his career, he managed many technology-based businesses in Japan, China, Southeast Asia, the United States, Northern Europe and the Australasian region, gaining exposure to many cultures and traditions. His love of travel gave birth to the storyline of “Bad Chemistry,” which is his debut novel. He currently lives in the United Kingdom with his wife. To learn more about Hudson, please visit paulstephenhudson.com.

Xlibris Publishing, an Author Solutions, LLC imprint, is a self-publishing services provider created in 1997 by authors, for authors. By focusing on the needs of creative writers and artists and adopting the latest print-on-demand publishing technology and strategies, we provide expert publishing services with direct and personal access to quality publication in hardcover, trade paperback, custom leather-bound and full-color formats. To date, Xlibris has helped to publish more than 60,000 titles. For more information, visit xlibris.com or call 1-888-795-4274 to receive a free publishing guide.

Attachment

• 815751HighRes

Lindsay, Ontario, Canada, Dec. 15, 2020 (GLOBE NEWSWIRE) — Holsag, a manufacturer of fine wood and faux wood chairs, has announced a new product feature to help keep customers safe in the age of COVID-19. Starting in January of 2021, most products will come standard with a catalyzed lacquer finish that includes an antimicrobial coating. No upcharge will be applied for this crucial customer benefit.

“Holsag has long been known for its durable, long-lasting finish and quality construction,” said Wayne Cockburn, sales director for Holsag. “Doing it right has always been our priority. At the onset of the COVID-19 pandemic, we began talking to our customers about how we could help in the struggle to keep surfaces clean and safe. As a result, our finish will now include a long-lasting antimicrobial coating. This coating adds a barrier of protection that helps keep surfaces cleaner by inhibiting the growth of a broad spectrum of bacteria, viruses, mold and mildew on the surfaces you touch.”

A wooden furniture finish that includes an antimicrobial formula prevents the growth of bacteria and some viruses. Products finished with this formula have been proven to be environmentally friendly while protecting the health of those who use the products by preventing the spread of germs.

“At the beginning of the COVID-19 pandemic, we questioned what could be done to make our products safer for the markets we serve,” said Scott Wilson, managing director of operations for Holsag. “In consultation with our valued customers, the most asked question was if the Holsag finish was Antimicrobial and how to best clean our product. We consulted our finishing supplier and worked with them to prove out a new antimicrobial additive that retains the benefits of our extremely durable, long-lasting finish while answering the needs of our valued customers.”

Learn more about this new product finish and how it works by visiting holsag.com/antimicrobial. Find a list of the products that include this new finish by visiting our website, Holsag.com.

Holsag has served the senior living and hospitality markets for more than 20 years. The company takes great pride in using sustainably sourced wood for chairs crafted in North America. Holsag became a MITY Inc. product brand in January of 2017. Learn more at mityinc.com

###

About Holsag

Holsag is committed to delivering solid wood chairs manufactured in Lindsay, Ontario with fine European Beech hardwood that is sustainably sourced from forests in Europe. The company uses only the best materials for chairs crafted to serve customers in senior living, hospitality and education. A collection of faux wood chairs is manufactured to serve the healthcare, hospitality and senior living markets. Holsag joined parent company, MITY Incorporated, in January of 2017.

Other MITY product brands include MityLite®, Bertolini®, XpressPort® and BRODA®. Visit mityinc.com for details.

Attachments

• MalmoArmChairs
• Malmo_FAMILY_Corduroy_RushmoreSilt

LOS ANGELES, Dec. 15, 2020 (GLOBE NEWSWIRE) — The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.  Investors have until the deadlines listed below to file a lead plaintiff motion.

Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected].

HP Inc. (NYSE: HPQ)
Class Period:   November 6, 2015 – June 21, 2016
Lead Plaintiff Deadline: January 4, 2021

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose: (1) that HP’s channel inventory management and sales practices resulted in the sale of supplies to customers that did not need or want the product in order to artificially increase revenues and profits; (2) that HP’s channel inventory management and sales practices resulted in the sale of supplies to customers outside of designated regions at unsustainable discounts in order to artificially increase revenues and profits; (3) that HP’s channel inventory management and sales practices resulted in the sale of supplies at steep discounts to customers to encourage those customers to sell the supplies further down the supply channel, out of HP’s inventory management metrics; and (4) that, as a result of the foregoing, defendants’ statements about the Company’s business condition and prospects were materially false and misleading when made.

Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT)
Class Period:   September 28, 2019 – October 7, 2020
Lead Plaintiff Deadline: January 4, 2021

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Defendants downplayed the true scope and severity of safety concerns associated with Ocaliva’s use in treating PBC; (2) the foregoing increased the likelihood of an FDA investigation into Ocaliva’s development, thereby jeopardizing Ocaliva’s continued marketability and the sustainability of its sales; (3) any purported benefits associated with OCA’s efficacy in treating NASH were outweighed by the risks of its use; (4) as a result, the FDA was unlikely to approve the Company’s NDA for OCA in treating patients with liver fibrosis due to NASH; and (5) as a result of all the foregoing, the Company’s public statements were materially false and misleading at all relevant times.

Neovasc Inc. (NASDAQ: NVCN)
Class Period: October 10, 2018 – October 27, 2020
Lead Plaintiff Deadline: January 5, 20201

Shareholders with $500,000 losses or more are encouraged to contact the firm

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors: (1) that the results of COSIRA, Neovasc’s clinical study for the Reducer, contained imbalances in missing information present in the control group versus the treatment group, including significant missing information for secondary endpoints but none for the primary endpoint; (2) that the imbalance in missing information indicated that control subjects were aware of their treatment assignment (not blinded) and less inclined to participate in additional data collection; (3) that blinding is critical when studying a placebo-responsive condition such as angina; (4) that the lack of blinding assessment made the primary endpoint difficult to interpret; (5) that, as a result of the foregoing, the FDA was reasonably likely to require additional premarket clinical data; (6) that, as a result, the Company’s PMA for Reducer was unlikely to be approved without additional clinical data; and (7) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Follow us for updates on Twitter: twitter.com/FRC_LAW.

To be a member of these class actions, you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. If you wish to learn more about these class actions, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Frank R. Cruz, of The Law Offices of Frank R. Cruz, 1999 Avenue of the Stars, Suite 1100, Los Angeles, California 90067 at 310-914-5007, by email to [email protected], or visit our website at www.frankcruzlaw.com.  If you inquire by email please include your mailing address, telephone number, and number of shares purchased.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

The Law Offices of Frank R. Cruz, Los Angeles
Frank R. Cruz, 310-914-5007
[email protected]
www.frankcruzlaw.com

LOS ANGELES, Dec. 15, 2020 (GLOBE NEWSWIRE) —

Glancy Prongay & Murray LLP (“GPM”) reminds investors of the upcoming December 29, 2020 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or otherwise acquired Wells Fargo & Company (“Wells Fargo” or the “Company”) (NYSE: WFC) common stock between October 13, 2017 and October 13, 2020, inclusive (the “Class Period”).

If you suffered a loss on your Wells Fargo investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at https://www.glancylaw.com/cases/wells-fargo-and-company/.You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

On April 14, 2020, Wells Fargo announced its first quarter 2020 financial results in a press release. Therein, the Company announced a $4 billion provision expense to account for expected credit delinquencies, including $940 million in net charge-offs on loans and debt securities and a $3.1 billion reserve build.

On this news, the Company’s stock price fell $4.54, or 14%, over three consecutive trading sessions to close at $26.89 per share on April 16, 2020.

On May 5, 2020, Wells Fargo filed its quarterly report with the SEC for first quarter 2020, in which it stated that Wells Fargo’s collateralized loan obligations (“CLOs”) investments fell 9% and that the Company suffered $1.7 billion in unrealized losses on its CLO investments during the quarter.

On this news, the Company’s stock price fell $1.74, or 6%, over two consecutive trading sessions to close at $25.61 per share on May 6, 2020.

On June 10, 2020, Wells Fargo’s Chief Financial Officer, John Shrewsberry, presented at the Morgan Stanley Virtual US Financials Conference, during which he stated that the second quarter reserve build would be even “bigger than the first quarter” due to continued deterioration in the Company’s credit portfolio.

On this news, the Company’s stock price fell $5.84, or 18%, over two consecutive trading sessions to close at $26.79 per share on June 11, 2020.

On July 14, 2020, Wells Fargo announced its second quarter 2020 financial results in a press release, disclosing a $9.5 billion provision expense to account for expected credit delinquencies.

On this news, the Company’s stock price fell $1.16, or 5%, to close at $24.25 per share on July 14, 2020.

On October 14, 2020, Wells Fargo announced a $769 million provision expense for third quarter 2020, but the Company’s CFO stated that further deterioration of the credit portfolio had been forestalled due to short-term customer accommodations provided since the start of the pandemic.

On this news, the Company’s stock price fell $1.49, or 6%, to close at $23.25 per share on October 14, 2020.

The complaint filed alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Wells Fargo had systematically failed to follow appropriate underwriting standards and due diligence guidelines in issuing billions of dollars’ worth of commercial loans, including by inflating the net income and future expected cash flows of its commercial clients to justify issuing excessive loan amounts; (2) a materially higher proportion of Wells Fargo’s commercial loans were to customers of poor credit quality and/or at a substantially higher risk of default than disclosed to investors; (3) Wells Fargo had failed to timely write down commercial loans, CLOs and CMBS on its books that had suffered impairments; (4) Wells Fargo had materially understated the reserves needed for expected credit losses in its commercial portfolios; (5) Wells Fargo had systematically misrepresented the credit quality and likelihood of default of the loans it packaged and securitized into CLOs and CMBS, including by artificially inflating the net income and expected cash flows of its commercial clients in loan and securitization documentation; (6) the CLO and CMBS-related loans issued and investment securities held by Wells Fargo were of lower credit quality and worth far less than represented to investors; (7) as a result of the foregoing, the Company’s statements regarding the credit quality of its commercial loans, its underwriting and due diligence practices, and the value of its CLO and CMBS books were materially false and misleading; and (8) as a result of the foregoing, the Company was exposed to severe undisclosed risks of financial, reputational and legal harm, in particular in the event of significant and sustained stress in the commercial credit markets.

Follow us for updates on LinkedIn, Twitter, or Facebook.

If you purchased Wells Fargo common stock during the Class Period, you may move the Court no later than December 29, 2020 to ask the Court to appoint you as lead plaintiff. To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Charles Linehan, Esquire, of GPM, 1925 Century Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to [email protected], or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number and number of shares purchased. 

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Charles H. Linehan, 310-201-9150 or 888-773-9224
1925 Century Park East, Suite 2100
Los Angeles, CA 90067
www.glancylaw.com  
[email protected]